Genomic aberrations relate early and advanced stage ovarian cancer

A. Zaal, W.J. Peyrot, P.M.J.J. Berns, M.E.L. van der Burg, J.H.W. Veerbeek, J.B. Trimbos, I. Cadron, P.J. van Diest, W.N. van Wieringen, O. Krijgsman, G.A. Meijer, J.M.J. Piek, P.J. Timmers, I. Vergote, R.H. Verheijen, B. Ylstra, R.P. Zweemer

Research output: Contribution to JournalArticleAcademicpeer-review


Background Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events. Methods Sixteen early and sixteen advanced stage ovarian carcinomas, matched for histological subtype and differentiation grade, were included. Genomic aberrations were compared for each early and advanced stage ovarian cancer by array comparative genomic hybridization. To study how the aberrations correlate to the clinical characteristics of the tumors we clustered tumors based on the genomic aberrations. Results The genomic aberration patterns in advanced stage cancer equalled those in early stage, but were more frequent in advanced stage (p=0.012). Unsupervised clustering based on genomic aberrations yielded two clusters that significantly discriminated early from advanced stage (p= 0.001), and that did differ significantly in survival (p= 0.002). These clusters however did give a more accurate prognosis than histological subtype or differentiation grade. Conclusion This study indicates that advanced stage ovarian cancer either progresses from early stage or from a common precursor lesion but that they do not arise from distinct carcinogenic molecular events. Furthermore, we show that array comparative genomic hybridization has the potential to identify clinically distinct patients. © The Author(s) 2012.
Original languageEnglish
Pages (from-to)181-188
JournalCellular Oncology
Issue number3
Publication statusPublished - 2012


Dive into the research topics of 'Genomic aberrations relate early and advanced stage ovarian cancer'. Together they form a unique fingerprint.

Cite this